Meet the team
Learn more about our expertise
Martin trained as a biochemist at the University of Edinburgh and then did a post doc in Professor John Cooper’s lab at Washington University, St. Louis, USA, working on the detailed characterisation, biochemically and in vivo, of a group of proteins that regulate the actin cyctoskeleton. He then returned to Edinburgh in 2004 and worked with Professor Walkinshaw on the development of a series of analytical methodologies for producing, purifying, screening and analysing protein:ligand interactions. This underpinned a large body of work related to the field of molecular recognition and drug design/discovery, leading to the framework that would become the EPPF. He has been the manager of the EPPF since it opened in April of 2008 and became a senior lecturer in biochemistry in 2014.
Liz trained as a chemist at the University of Edinburgh and after being a principal teacher of physics, and teaching for 13 years in various high schools, returned to Edinburgh and gained her MSc. and PhD. in drug design, virtual screening and biophysical techniques for identify and characterise small molecule:protein complexes (immunophilins). Following this, Liz joined the EPPF in 2010 and has been an integral member of the core team since, providing support and expert input on a very wide range of production and characterisation projects and targets, for both internal and external collaborations. Liz has gained a reputation for exacting biophysical and structural analysis of challenging protien:lignd interactions, especially using ITC, DLS and SAXS and for her work on the structure and function of a family of very large proteins (LifA) involved in bacterial infection.
Matthew trained as a chemist at the University of Edinburgh and gained his PhD. in the design and synthesis of inhibitors of trypanosomatid glycolysis. Matt joined the EPPF team in 2011 and has been an integral member of the core team since, providing support and expert input on a very wide range of production and characterisation projects and targets, for both internal and external collaborations. Matt has gained a reputation for the design and implementation of automated multi-step purification strategies for untagged proteins, biophysical and detailed structural analysis of glycolytic and metabolic proteins and their allosteric ligand interactions, as well as for the production and characterisation of nano-bodies as therapeutics and molecular tools.